Main Menu

ACTION

Adjuvant Cytotoxic Chemotherapy in Older Women (ACTION)

Disease site: Breast cancer

Treatment modality: Chemotherapy

Status: Closed

Trial details

ACTION was an NCRI phase III randomised controlled trial testing the benefit and tolerability of adjuvant chemotherapy in patients aged 70 and over with early stage ER negative or ER weakly positive breast cancer.

The aim of this trial was to address the following hypotheses:

  1. that adjuvant chemotherapy (either AC or EC) will increase the relapse free survival interval in older women with high risk breast cancer, and
  2. that two weekly (accelerated) therapy with GCSF support will not cause undue toxicity in this patient group, compared to the standard three weekly and that both chemotherapy regimens will be acceptable and tolerated in this group of patients

Chief Investigator: Professor Robert Leonard, Charing Cross Hospital, London

ICR-CTSU Scientific Lead: Professor Judith Bliss

Trial management contactaction-icrctsu@icr.ac.uk

ISRCTN: 41708421

Sponsor: Institute of Cancer Research and Imperial College Healthcare NHS Trust

Funding: Cancer Research UK (CRUK/06/002), AMGEN

Publications and presentations

Leonard R, Ballinger R, Cameron D, et al. Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br. J. Cancer 2011;105(9):1260-6.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.